Xylem (NYSE:XYL) Director D Christian Koch Purchases 11,000 Shares of Stock

Xylem Inc. (NYSE:XYL) Director D Koch bought 11,000 shares of the business’s stock in a transaction dated Thursday, October 29th. The stock was acquired at an average cost of $89.60 per share, for a total transaction of $985,600.00. Following the purchase, the director owned 12,247 shares in the company, valued at approximately $1,097,331.20. This trade represents a 882.12% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Xylem Stock Performance

NYSE:XYL opened at $90.74 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $20.81 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 1.47 and a beta of 1.00. The firm’s fifty day simple moving average is $105.47 and its 200 day simple moving average is $117.80. Xylem Inc. has a twelve month low of $87.40 and a twelve month high of $154.27.

Xylem (NYSE:XYL) last announced its quarterly earnings results on Tuesday, October 27th. The industrial products company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.45 by ($0.01). Xylem had a return on equity of 12.06% and a net margin of 11.94%. The business had revenue of $2.20 billion for the quarter, compared to analysts’ expectations of $2.28 billion. During the same period last year, the company posted $1.37 earnings per share. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. As a group, equities research analysts expect that Xylem Inc. will post 5.47 earnings per share for the current fiscal year.

Xylem Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 24th. Shareholders of record on Thursday, August 27th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date was Thursday, August 27th. Xylem’s payout ratio is currently 40.95%.

Hedge Funds Weigh In On Xylem

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GRIMES & Co WEALTH MANAGEMENT LLC grew its holdings in shares of Xylem by 2.2% during the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 57,742 shares of the industrial products company’s stock valued at $5,848,000 after purchasing an additional 1,235 shares during the last quarter. Next Level Wealth Planning LLC acquired a new stake in shares of Xylem during the 3rd quarter worth approximately $71,000. Woodmont Investment Counsel LLC lifted its holdings in shares of Xylem by 5.7% in the 3rd quarter. Woodmont Investment Counsel LLC now owns 49,043 shares of the industrial products company’s stock worth $4,967,000 after purchasing an additional 2,655 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Xylem by 9.5% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 116,885 shares of the industrial products company’s stock worth $11,834,000 after purchasing an additional 10,149 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Xylem by 0.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 538,198 shares of the industrial products company’s stock worth $54,503,000 after purchasing an additional 3,000 shares during the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Oppenheimer lowered their target price on Xylem from $150.00 to $135.00 and set an “outperform” rating for the company in a research note on Wednesday. Robert W. Baird set a $123.00 price target on Xylem in a research report on Wednesday. BNP Paribas Exane reduced their price target on Xylem from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. cut Xylem from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $118.00 to $90.00 in a report on Wednesday. Finally, Royal Bank Of Canada lowered their price objective on shares of Xylem from $135.00 to $125.00 and set an “outperform” rating for the company in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $121.31.

More Xylem News

Here are the key news stories impacting Xylem this week:

• Positive Sentiment: Director D. Christian Koch purchased 11,000 shares worth approximately $985,600, substantially increasing his direct ownership. The transaction may signal confidence that the recent decline has created an attractive entry point. SEC insider trading filing
• Positive Sentiment: Options activity was notably bullish on Thursday, with traders buying 20,508 call options—roughly 771% above typical volume—suggesting some investors are positioning for a rebound.
• Positive Sentiment: RBC Capital reaffirmed its buy rating, while its broader analyst coverage set a “moderate buy” rating and a $125 price target. Other firms, including Citigroup, BNP Paribas Exane, Stifel and Oppenheimer, maintained positive ratings despite lowering their targets. RBC rating article
• Neutral Sentiment: Xylem announced divestitures and a new three-segment structure, which could improve strategic focus and portfolio efficiency but may create near-term execution and transition risks. Xylem restructuring article
• Negative Sentiment: Third-quarter revenue was $2.20 billion, below the $2.28 billion consensus estimate, while adjusted EPS of $1.44 narrowly missed expectations. Revenue declined 3% year over year, and Xylem cut its 2026 outlook. Xylem earnings article
• Negative Sentiment: Barclays downgraded Xylem to equal weight from overweight, while JPMorgan moved to underweight and UBS lowered its target to $99 with a neutral rating. Stifel also cut its target to $114. These actions highlight persistent concerns about near-term growth and valuation. Barclays downgrade article
• Negative Sentiment: Unusual put-option activity, with put volume several times above average, and a law firm’s announced investigation into potential securities-law violations add further risk and uncertainty. Xylem investigation notice

Xylem Company Profile

Xylem Inc (NYSE: XYL) is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company’s products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.